详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Expert consensus on the combination of Anti-EGFR monoclonal antibodies and immune checkpoint inhibitors in the treatment of head and neck squamous cell carcinoma

0| 认领 | 链接全文 |

文献详情

资源类型：

文献类型：

刊名：

ISSN：

年份：

卷：

页码：

DOI：

关键词： Head and neck squamous cell carcinoma Anti-epidermal growth factor receptor monoclonal antibodies Immune checkpoint inhibitors Combination treatment Expert consensus

摘要：

Head and neck squamous cell carcinoma (HNSCC) is the most prevalent type of head and neck cancer; however, treatment outcomes and patient prognosis remain suboptimal. Although the survival of patients with HNSCC has improved with the widespread use of anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) and immune checkpoint inhibitors (ICIs), there remains considerable potential for further improvement. Recent studies suggest that the combination of anti-EGFR monoclonal antibodies and ICIs demonstrates promising efficacy and safety, which has been recommended by international guidelines for patients with recurrent or metastatic disease. Nevertheless, the application of this combination therapy remains in the early stages of exploration, and numerous questions concerning its standardized clinical use remain unanswered, including the mechanisms underlying the synergistic effects of individual agents, therapeutic value across different patient populations, and safety considerations. The Expert Committee of Head and Neck Cancer of the Chinese Society of Clinical Oncology (CSCO) organized an expert panel to develop this expert consensus on the combination of anti-EGFR mAbs and ICIs in the treatment of HNSCC through multiple rounds of discussion based on evidence-based medicine and clinical practice experience. This consensus provides guidance on the mechanisms of treatment with anti-EGFR mAbs plus ICIs, stratified treatment approaches, applications in special populations, and safety management. It is hoped that this consensus will provide clearer and more practical guidance for clinicians, promote the rational application of this combination therapy in clinical practice, and offer more treatment options for patients with HNSCC.Copyright © 2025 The Authors. Published by Elsevier Ltd.. All rights reserved.

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2025]版中科院分区表Review为是的期刊

：

大类 | 1 区

医学

小类 | 2 区肿瘤学

最新[2025]版

：

大类 | 1 区

医学

小类 | 2 区肿瘤学

专家组成员：

Xue Liqiong （Department of Oncology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China） Xu Tingting （Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China;Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China） Cao Guochun （Department of Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China） Chen Xiaozhong （Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, China） Fang Meiyu （Department of Head and Neck and Rare Oncology, Zhejiang Cancer Hospital, Hangzhou, China） Feng Mei

（Department of Oncology, The Third People’s Hospital of Sichuan Province, Chengdu, China;Department of Radiation Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China） Gui Lin （Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021, China） Han Fei （Department of Radiation Oncology, Sun Yat-sen University Cancer Centre, Guangzhou, China） Han Yaqian （Department of Head and Neck Radiotherapy, Hunan Cancer Hospital, Changsha, China） Hao Chuncheng （Department of Head and Neck Radiation Oncology, Harbin Medical University Cancer Hospital, Harbin, China） Hu Man （Department of Head and Neck Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Jinan, China） Huang Wenxiao （Department of Head and Neck Surgery, Hunan Cancer Hospital, Changsha, China） Ji Dongmei （Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China;Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China） Jiang Hao （Department of Radiation Oncology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, China） Lin Shaojun （Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fujian Medical University, Fujian, China） Liu Lei （Department of Head and Neck Oncology, West China Hospital, Sichuan University, Chengdu, China） Liu Zhigang （Cancer Center, Dongguan Key Laboratory of Precision Diagnosis and Treatment for Tumors, The Tenth Affiliated Hospital, Southern Medical University (Dongguan People’s Hospital), Dongguan, China） Lu Haijun （Department of Radiation Oncology, The Affiliated Hospital of Qingdao University, Qingdao, China） Qu Song （Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning, China） Ren Guoxin （Department of Oral Maxillofacial-Head and Neck Oncology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China） Song Ming （Department of Head and Neck Surgery, Sun Yat-Sen University Cancer Centre, Guangzhou, China） Wang Peiguo （Department of Radiation Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China） Wang Xiaoshen （Department of Radiation Oncology, Eye & ENT Hospital, Fudan University, Shanghai, China） Yang Kunyu （Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China） Yu Aimin （Department of Otorhinolaryngology Head and Neck Surgery, Northern Jiangsu People’s Hospital Affiliated to Yangzhou University, Yangzhou, China） Zhang Jie （Department of Oral and Maxillofacial Surgery, Peking University Hospital of Stomatology, Beijing, China） Zhang Shichuan

（Department of Radiation Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China） Zhang Xinxin （Senior Department of Otolaryngology Head and Neck Surgery, Chinese PLA General Hospital, Beijing 100853, China;National Clinical Research Center for Otolaryngologic Diseases, Beijing, China） Zhang Ye （Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China）

本院专家组成员：

Feng Mei[7,8]

通讯作者：

Guo Ye （pattrickguo@gmail.com） Hu Chaosu （hucsu62@163.com）

推荐引用方式(GB/T 7714)：

APA：

MLA：